Share This Author
Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics
Cortisol and Cytokines in Chronic and Treatment-Resistant Patients with Schizophrenia: Association with Psychopathology and Response to Antipsychotics
The results suggest that the imbalance in the HPA axis and cytokine system in patients with SCH is implicated in clinical symptoms, and is improved with atypical antipsychotic treatment.
Free radicals, antioxidant defense systems, and schizophrenia
Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Improvement of cognition with tropisetron appeared to be associated with normalization in P50 deficits, and α7 nAChR agonists appear to be a promising therapeutic approach for the treatment of cognitive deficits that are related to abnormal P50 suppression in schizophrenia.
Cognitive and serum BDNF correlates of BDNF Val66Met gene polymorphism in patients with schizophrenia and normal controls
It is demonstrated that visuospatial/constructional abilities significantly differed by genotype but not genotype × diagnosis, and the Val allele was associated with better visuSpatial/ constructional performance in both schizophrenic patients and healthy controls and the BDNF Met variant may be specific to attentional decrements in schizophrenia.
Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology
Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements
Identifying a clinical signature of suicidality among patients with mood disorders: A pilot study using a machine learning approach.
Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics